Long-term safety and immunogenicity of the M72/AS01(E) candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial

OBJECTIVES: To assess the long-term safety and immunogenicity of the M72/ Adjuvant System (AS01(E)) candidate tuberculosis (TB) vaccine up to 3 years post-dose 2 (Y3) in human immunodeficiency virus (HIV)-positive (HIV+) and HIV-negative (HIV−) Indian adults. METHODS: This phase II, double-blind, ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Kumarasamy, Nagalingeswaran, Poongulali, Selvamuthu, Beulah, Faith Esther, Akite, Elaine Jacqueline, Ayuk, Leo Njock, Bollaerts, Anne, Demoitié, Marie-Ange, Jongert, Erik, Ofori-Anyinam, Opokua, Van Der Meeren, Olivier
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6250513/
https://ncbi.nlm.nih.gov/pubmed/30407329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados